Argus Research Believes Humana Inc (NYSE: HUM) Won’t Stop Here

By Jason Carr

In a report released today, David Toung from Argus Research upgraded Humana Inc (NYSE: HUM) to Buy. The company’s shares closed yesterday at $230.26, close to its 52-week high of $236.35.

According to, Toung is a 4-star analyst with an average return of 11.7% and a 66.7% success rate. Toung covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Humana Inc has an analyst consensus of Moderate Buy, with a price target consensus of $220.75.

Based on Humana Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $13.76 billion and quarterly net profit of $1.12 billion. In comparison, last year the company earned revenue of $13.8 billion and had a net profit of $234 million.

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. Last month, Jody Bilney, the SVP & Chief Consumer Officer of HUM sold 4,600 shares for a total of $1,058,736.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Humana Inc. is a health and well-being company focused on making it easy for people to achieve their best health with clinical excellence through coordinated care. Its strategy integrates care delivery, the member experience, and clinical and consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the millions of people they serve across the country. The company operates through the following segments: Retail, Group and Specialty, Healthcare Services, and Individual Commercial. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its Medicare Supplement and state-based contracts businesses. State-based contracts include those with various states to provide Medicaid, dual eligible, and Long-Term Support Services benefits. In addition, this segment also includes the company’s contract with the Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program. The Group and Specialty segment consists of employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, and other supplemental health and voluntary insurance benefits. In addition, the segment also includes the company’s Administrative Services Only products and its military services businesses, primarily the TRICARE South Region contract. The Healthcare Services segment includes services offered to the company’s health plan members as well as to third parties, including pharmacy solutions, provider services, and clinical programs, such as home health and other services and capabilities to promote wellness and advance population health. The Individual Commercial segment consists of Individual Commercial products marketed under the HumanaOne brand. For 2017, the company offers on-exchange products as well as certain grandfathered policies issued prior to the enactment of the Health Care Reform Law. Off-exchange products were also offered in 2016. As announced in 2017, the company plans to exit this business in 2018. The company was founded by David A. Jones, Sr. and Wendell Cherry in 1961 and is headquartered in Louisville, KY.